Monopar Therapeutics (NASDAQ:MNPR) Given New $85.00 Price Target at Chardan Capital

Key Points

• Monopar Therapeutics received a new price target of $85.00 from Chardan Capital, indicating a potential upside of 16.37% from its previous closing price.
• Multiple research firms have issued optimistic ratings for the company, with average analyst targets ranging around $80.22 and several firm price objectives exceeding $100.00.
• Institutional investors are active in the stock, with recent acquisitions by firms such as Affinity Asset Advisors and Geode Capital Management, which significantly increased their stakes in the company.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) had its price target boosted by equities research analysts at Chardan Capital from $60.00 to $85.00 in a research note issued to investors on Thursday,Benzinga reports. The firm currently has a "buy" rating on the stock. Chardan Capital's price target indicates a potential upside of 16.37% from the company's previous close.

Several other research firms also recently issued reports on MNPR. HC Wainwright assumed coverage on Monopar Therapeutics in a research note on Tuesday, August 26th. They issued a "buy" rating and a $70.00 price objective for the company. Oppenheimer assumed coverage on Monopar Therapeutics in a research note on Wednesday, September 3rd. They issued an "outperform" rating and a $77.00 price objective for the company. Lake Street Capital assumed coverage on Monopar Therapeutics in a research note on Tuesday. They issued a "buy" rating and a $106.00 price objective for the company. BTIG Research upped their price objective on Monopar Therapeutics from $87.00 to $104.00 and gave the company a "buy" rating in a research note on Thursday. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $74.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. One investment analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Monopar Therapeutics has an average rating of "Buy" and an average target price of $80.22.

Monopar Therapeutics Trading Up 7.9%

MNPR stock opened at $73.04 on Thursday. The stock has a market capitalization of $450.66 million, a P/E ratio of -21.93 and a beta of 1.20. Monopar Therapeutics has a 12 month low of $4.12 and a 12 month high of $74.00. The firm has a 50-day moving average price of $43.25 and a 200-day moving average price of $38.70.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings data on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12. As a group, equities analysts predict that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Insider Buying and Selling at Monopar Therapeutics

In other news, Director Christopher M. Starr sold 16,800 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The shares were sold at an average price of $40.00, for a total transaction of $672,000.00. Following the completion of the sale, the director owned 5,173 shares of the company's stock, valued at $206,920. This trade represents a 76.46% decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this link. Also, Director Kim R. Tsuchimoto sold 8,904 shares of the firm's stock in a transaction that occurred on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the sale, the director directly owned 11,486 shares of the company's stock, valued at approximately $459,440. This trade represents a 43.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 42,504 shares of company stock valued at $1,700,160. 20.50% of the stock is currently owned by company insiders.

Institutional Trading of Monopar Therapeutics

Several large investors have recently modified their holdings of MNPR. Affinity Asset Advisors LLC acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $2,257,000. Geode Capital Management LLC grew its position in shares of Monopar Therapeutics by 99.7% during the 2nd quarter. Geode Capital Management LLC now owns 96,919 shares of the company's stock worth $3,468,000 after buying an additional 48,379 shares during the period. Goldman Sachs Group Inc. acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $673,000. Jane Street Group LLC acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $377,000. Finally, OMERS ADMINISTRATION Corp acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $328,000. Institutional investors and hedge funds own 1.83% of the company's stock.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.